News

LATEST NEWS



icon2022/07/04

    Novation and UofMontreal present at Target ALS annual meeting in Boston, MA

icon2022/01/19

    Dr. Roland Bürli joins Novation's Scientific Advisory Board

icon2021/04/30

    Novation and UofMontreal/CRCHUM consortia present at Target ALS annual meeting

icon2020/07/13

    Target ALS award for Novation and UofMontreal/CRCHUM collaboration

icon2018/12/04

    Novation presents at first RNA-targeted drug discovery summit

icon2016/01/19

    Dr. Andrew MacKenzie joins Novation's Scientific Advisory Board

icon2016/01/01

    Novation files US patent on oral cytokine inhibitor

icon2013/05/07

    Novation establishes Research Collaboration with Boehringer Ingelheim

icon2013/04/22

    Novation receives Notice of Issuance by Canadian Patent Office for QUEST mRNA Drug Discovery Technology

icon2012/10/22

    Novation receives Notice of Allowance by Canadian Patent Office for QUEST mRNA Drug Discovery Technology

icon2010/07/20

    Novation receives contribution from NRC IRAP

icon2009/06/11

    Novation and Cancer Therapeutics collaborate on new cancer therapies

icon2009/06/02

    Notice of Allowance from US Patent Office for Quest Drug Discovery technology

icon2009/01/07

    Quest drug discovery assay available for identifying inhibitors of IL-6

icon2008/11/17

    Quest oncology drug discovery assays for intractable cancer targets

icon2008/10/30

    Drug discovery assay for identifying new therapeutics for neurological diseases

icon2008/09/11

    Dr. Inder Verma joins Novation's Scientific Advisory Board

icon2007/09/04

    Novation receives Notice of Intent to Grant from European Patent Office

icon2006/02/05

    Dr. Alan Lewis and Dr. Tim Harris appointed to Novation's Board of Directors

icon2005/11/23

    Novation Commences mRNA Small Molecule Drug Discovery Project with Novartis